The EPISODE trial of psychedelic-assisted therapy for ‘treatment-resistant depression’ finds only modest effects, with a few clear responders, but lingering methodological questions.
[read the full story...]
ADHD medication associated with reduced rates of suicide, substance misuse, transport accidents and criminality in Swedish study of 148,581 people.
[read the full story...]
How safe is it to treat ADHD in people with schizophrenia spectrum disorders? New long-term data offers pragmatic reassurance, but also some warnings.
[read the full story...]
Can ketamine help people with treatment-resistant depression, regardless of childhood trauma history? This new study suggests that trauma load and severity may not influence treatment outcomes.
[read the full story...]
No drugs are officially approved for borderline personality disorder, yet prescribing is widespread. This systematic review explores why clinicians prescribe, the pressures they face, and what it means for patient care.
[read the full story...]
Beta-blockers like propranolol are being prescribed more often for anxiety in UK primary care, even though they don’t appear in national guidelines. This new qualitative study explores why GPs turn to them, and what that says about evidence, safety, and patient choice.
[read the full story...]
From weight gain to heart rhythm changes, sexual dysfunction to sleep problems — the physical side effects of psychiatric drugs are vast, complex, and often overlooked. This blog distils key insights from a new Lancet Commission published today; to help clinicians and patients make safer, more informed prescribing decisions.
[read the full story...]
Eleanor Dawkins explores a new review and meta-analysis suggesting that cognitive impairment is linked with anticholinergic medication in psychosis, providing grounds for more careful monitoring and review of medications.
[read the full story...]
This Swedish cohort study, blogged by Duncan Swiffen, is yet more evidence for lithium as an excellent treatment for people with bipolar disorder. This time it comes out on top in terms of preventing depression-related hospitalisation.
[read the full story...]
Kirsten Lawson and Douglas Badenoch review the new randomised controlled trial by Cleare et al, published today in The Lancet Psychiatry, directly comparing the clinical and cost effectiveness of lithium and quetiapine as augmentation treatments for patients with ‘treatment resistant depression’.
[read the full story...]
